Zhejiang Hisoar Pharmaceutical 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Guorui Xu

최고 경영자

CN¥1.0m

총 보상

CEO 급여 비율	n/a
CEO 임기	10yrs
CEO 소유권	0.03%
경영진 평균 재임 기간	10yrs
이사회 평균 재임 기간	2.4yrs

최근 관리 업데이트

Recent updates

Zhejiang Hisoar Pharmaceutical Co., Ltd.'s (SZSE:002099) Price Is Out Of Tune With Revenues

Sep 27

Does Zhejiang Hisoar Pharmaceutical (SZSE:002099) Have A Healthy Balance Sheet?

Aug 30

Zhejiang Hisoar Pharmaceutical (SZSE:002099) Has Debt But No Earnings; Should You Worry?

May 27

Zhejiang Hisoar Pharmaceutical Co., Ltd.'s (SZSE:002099) Shares Climb 28% But Its Business Is Yet to Catch Up

Mar 03

CEO

Guorui Xu (47 yo)

10yrs

테뉴어

CN¥1,000,600

보상

Mr. Guorui Xu serves as Non-Independent Director at Zhejiang Hisoar Pharmaceutical Co., Ltd. since November 30, 2022 and serves as its General Manager. He had been Deputy General Manager at Zhejiang Hisoar...

리더십 팀

이름	위치	테뉴어	보상	소유권
Guorui Xu	GM & Director	10yrs	CN¥1.00m	0.028% CN¥ 2.6m
Bing Yao	Vice President	1.1yrs	CN¥1.00m	데이터 없음
Wen Hua Mao	Deputy General Manager	11.3yrs	CN¥600.80k	0.085% CN¥ 7.7m
Haiyan Zhou	Accounting Supervisor	no data	데이터 없음	데이터 없음
Qing Pan	Vice President	no data	CN¥350.70k	데이터 없음

10.0yrs

평균 재임 기간

47yo

평균 연령

경험이 풍부한 관리: 002099 의 관리팀은 노련하고 경험 (평균 재직 기간 10 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Guorui Xu	GM & Director	2yrs	CN¥1.00m	0.028% CN¥ 2.6m
Bing Yao	Vice President	5yrs	CN¥1.00m	데이터 없음
Wei Zhong Gong	Member of the Supervisory Board	12.1yrs	데이터 없음	데이터 없음
Yangchao Wang	Chairman	5yrs	CN¥608.00k	0.13% CN¥ 11.7m
Minjie Chen	Employees Representative Chairman of Supervisory Board	5yrs	데이터 없음	데이터 없음
Jinyun Hu	Non-Employee Supervisor	2.8yrs	데이터 없음	데이터 없음
Hong Tao	Non-Independent Director	2yrs	CN¥48.30k	데이터 없음
Yongping Yu	Independent Director	2yrs	CN¥80.00k	데이터 없음
Jianmin Qian	Independent Director	2yrs	CN¥6.70k	데이터 없음
Chao Liang	Independent Director	2yrs	CN¥6.70k	데이터 없음

2.4yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 이사회: 002099 의 이사회는 경험(평균 재직 기간 2.4 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Zhejiang Hisoar Pharmaceutical 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Zhejiang Hisoar Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

Zhejiang Hisoar Pharmaceutical Co., Ltd. Elects Tao Hong as Non-Independent Director; and Yu Yongping, Qian Jianmin and Liang Chao as Independent Directors

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released

Zhejiang Hisoar Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Zhejiang Hisoar Pharmaceutical Co., Ltd.'s (SZSE:002099) Price Is Out Of Tune With Revenues

Second quarter 2024 earnings released: EPS: CN¥0.003 (vs CN¥0.013 loss in 2Q 2023)

Does Zhejiang Hisoar Pharmaceutical (SZSE:002099) Have A Healthy Balance Sheet?

Zhejiang Hisoar Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Zhejiang Hisoar Pharmaceutical (SZSE:002099) Has Debt But No Earnings; Should You Worry?

Third quarter 2023 earnings released: CN¥0.03 loss per share (vs CN¥0.021 profit in 3Q 2022)

Zhejiang Hisoar Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

Zhejiang Hisoar Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 29, 2024

Zhejiang Hisoar Pharmaceutical Co., Ltd.'s (SZSE:002099) Shares Climb 28% But Its Business Is Yet to Catch Up

Zhejiang Hisoar Pharmaceutical Co., Ltd. (SZSE:002099) announces an Equity Buyback for CNY 30 million worth of its shares.

Zhejiang Hisoar Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 29, 2024

Third quarter 2023 earnings released: CN¥0.03 loss per share (vs CN¥0.021 loss in 3Q 2022)

New minor risk - Share price stability

Zhejiang Hisoar Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

Second quarter 2023 earnings released: CN¥0.013 loss per share (vs CN¥0.061 profit in 2Q 2022)

Zhejiang Hisoar Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 24 May 2023

Zhejiang Hisoar Pharmaceutical Co., Ltd. Approves the Profit Distribution Proposal for 2022

First quarter 2023 earnings released: EPS: CN¥0.02 (vs CN¥0.05 in 1Q 2022)

Zhejiang Hisoar Pharmaceutical Co., Ltd. Elects Tao Hong as Non-Independent Director; and Yu Yongping, Qian Jianmin and Liang Chao as Independent Directors

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.021 (vs CN¥0.01 in 3Q 2021)

Zhejiang Hisoar Pharmaceutical Co., Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 25 May 2022

Zhejiang Hisoar Pharmaceutical Co., Ltd. Approves Dividend for 2021

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Zhejiang Hisoar Pharmaceutical Co., Ltd. Proposes Cash Dividend for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.01 (vs CN¥0.06 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.002 (vs CN¥0.10 in 2Q 2020)

Investor sentiment deteriorated over the past week

Zhejiang Hisoar Pharmaceutical Co., Ltd. Announces Dividend for 2020

Full year 2020 earnings released: EPS CN¥0.20 (vs CN¥0.48 in FY 2019)

Investor sentiment improved over the past week

Market bids up stock over the past week

New 90-day high: CN¥8.53

Third quarter earnings released

Zhejiang Hisoar Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

First half earnings released

Zhejiang Hisoar Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

New 90-day high - CN¥8.89

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령